Anatomical main group
V – VARIA
16Decisions
22Patient groups
Added benefit by patient group
- Considerable2
- Non-quantifiable2
- Not proven17
- Lesser benefit1
Subgroups
- V03 ALLE ÜBRIGEN THERAPEUTISCHEN MITTEL 11 decisions
- V08 KONTRASTMITTEL 2 decisions
- V09 RADIODIAGNOSTIKA 1 decision
- V10 RADIOTHERAPEUTIKA 2 decisions
Decisions, newest first
- 2026-08-20EluciremGadopiclenolNot proven
- 2026-01-22OndexxyaAndexanet alfaNot proven: 1 of 2 patient groupsLesser benefit: 1 of 2 patient groups
- 2025-07-17PedmarqsiNatriumthiosulfatNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-01-16LocametzGozetotidConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-09-19EluciremGadopiclenolNot proven
- 2024-08-01VeltassaPatiromerNot proven
- 2023-07-06Pluvicto(177Lu)LutetiumvipivotidtetraxetanConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-04-06KapruviaDifelikefalinNot proven
- 2022-10-06VoraxazeGlucarpidaseNon-quantifiable
- 2021-09-16LokelmaNatrium-ZirconiumcyclosilicatNot proven
- 2021-06-03VelphoroSucroferric OxyhydroxideNot proven
- 2020-10-01TybostCobicistatNot proven
- 2019-10-17XofigoRadium-223-dichloridNot proven: 2 of 2 patient groups
- 2018-09-20VeltassaPatiromerNot proven
- 2015-03-19VelphoroSucroferric OxyhydroxideNot proven: 2 of 2 patient groups
- 2014-09-18TybostCobicistatNot proven
Data status: 2026-10-29